Teva Pharmaceutical Industries Ltd. entered into a deal Monday to buy Auspex Pharmaceuticals Inc. for $3.2 billion.
The deal, which still requires stockholder and regulatory approval, calls for Teva (NYSE: TEVA) to pay Auspex stockholders $101 per share for their stock. Key shareholders of Auspex have entered into agreements indicating their support for the transaction, according to Teva.
Erez Vigodman, president and CEO of Teva, said the company is pursuing the deal to strengthen its central nervous system disorder product line.
Read the full story here.
For more business news, check out pbj.com.
Copyright bizjournal
